Monte Rosa Therapeutics, Inc. GLUE Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax

Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax at other companies

Edgewell Personal CareEPC

-$300K0.0%

Equitable HoldingsEQH

-$38M-124%

ADTRAN Holdings, Inc.ADTN

$66K+150%

TFS FinancialTFSL

$0—

SeaboardSEB

-$8M+70.4%

VontierVNT

$500K—

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.76B+361%

Enterprise value$1.64B+381%

P/S41×+38.6×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, after tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, after tax?: Monte Rosa Therapeutics, Inc. (GLUE) reported other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, after tax of -$55K in Q1 2026.